Preview

Вопросы современной педиатрии

Расширенный поиск

КАКИЕ ИММУНОМОДУЛЯТОРЫ НЕОБХОДИМЫ ЧАСТО БОЛЕЮЩИМ ДЕТЯМ? ОТ ПОНИМАНИЯ МЕХАНИЗМОВ ДЕЙСТВИЯ ПРЕПАРАТА К КЛИНИЧЕСКОЙ ЭФФЕКТИВНОСТИ

https://doi.org/10.15690/vsp.v13i1.921

Полный текст:

Аннотация

В статье проанализированы современные представления о механизмах действия пидотимода ― иммуномодулятора, исследования которого расширяют представления о возможностях регуляции иммунного ответа. Пидотимод представляет собой безопасный иммуномодулятор, эффективный как при профилактическом применении, так и в качестве лечебного средства, что подтверждено результатами контролируемых исследований с участием большого числа пациентов. Разработка новых методов исследования в клинической иммунологии позволила понять механизмы действия препарата in vivo, что, в свою очередь, стимулировало дальнейшее применение пидотимода в педиатрической практике.

Об авторе

А. В. Караулов
Первый Московский государственный медицинский университет им. И.М. Сеченова
Россия


Список литературы

1. Zemskov A.M., Zemskov V.M., Karaulov A.V. Klinicheskaya immunologiya [Clinical Immunology]. Moscow, GOETAR-Media, 2006. 320 p.

2. Kuznetsov V.P., Karaulov A.V. Leukinferon - mechanisms of therapeutic action and tactics immune. Int. J. Immunorehabilitation. 1998; 10: 66–75.

3. Sil'vestrov V.P., Karaulov A.V. Principles of immunoregulatory therapy of certain diseases of the respiratory system. Ter. arkhiv = Therapeutic archive. 1982; 4: 3–9.

4. Sil'vestrov V.P., Karaulov A.V. Antibacterial and immunomodulatory therapy of respiratory diseases. Ter. arkhiv = Therapeutic archive. 1983; 3: 3–9.

5. Karaulov A.V., Kalyuzhin O.V. Immunotropnye preparaty: printsipy primeneniya i klinicheskaya effektivnost' [Immunotropic Drugs: Principles and Application of Clinical Efficacy]. Moscow, MTsFER, 2007. 144 p.

6. Karaulov A.V., Kalyuzhin O.V. Immunotherapy of infectious diseases: problems and prospects. Ter. arkhiv = Therapeutic archive. 2013; 11: 100–108.

7. Karaulov A.V., Likov V.F., Kokushkov D.V. Kombinirovannaya immunokorrektsiya infektsionnykh zabolevanii respiratornogo trakta [Combination Immunotherapy of Infectious Diseases of the Respiratory Tract]. Moscow, 2008. 16 p.

8. Karaulov A.V., Sokurenko S.I., Klimov E.V. Application immunomodulator IRS 19 with recurrent respiratory diseases. RMZh = Russian medical journal. 2000; 8 (13–14): 552–553.

9. Bulgakova V.A., Balabolkin I.I., Ushakova V.V. Current state of sickly children. Pediatrich. farmakol. = Pediatric pharmacology. 2007; 4 (2): 48–52.

10. Namazova L.S., Volkov K.S., Torshkhoeva R.M., Alekseeva A.A. New features therapies sickly children. Pediatrich. farmakol. = Pediatric pharmacology. 2008; 5 (2): 12–20.

11. Karaulov A.V. Comment on the article AS Kolbina, AV Kharcheva "The use of immunostimulants in acute respiratory tract infections in children. Foreign experience - a view from the perspective of evidence-based medicine. Pediatrich. farmakol. = Pediatric pharmacology. 2007; 4: 6–7.

12. Karaulov A.V., Klimov E.V. Clinical efficacy of bacterial immunomodulators and their effect on humoral and secretory factors sickly children. Pediatriya = Pediatrics. 2001; 4: 86–90.

13. Karaulov A.V. Pidotimod drug - a new effective tool in immunotherapy and immunoprophylaxis of respiratory infections in children. Vopr. sovr. pediatrii = Current pediatrics. 2008; 7 (1): 96–101.

14. Karaulov A.V. Safety and efficacy of pidotimoda in acute and chronic bronchitis. Vopr. sovr. pediatrii = Current pediatrics. 2010; 9 (6): 139–144.

15. Karaulov A.V. Whether enhance the immune response of respiratory infections in children with allergic diseases? Data research and their implications for clinical practice. Vopr. sovr. pediatrii = Current pediatrics. 2011; 10 (6): 166–169.

16. Aivazis V., Hatzimichail A., Papachristou A., Valeri R., Iuga-Donca G. Clinical evaluation and changes of the respiratory epithelium function after administration of Pidotimod in Greek children with recurrent respiratory tract infections. Minerva Pediatr. 2002; 54: 345–349.

17. Huang J.H., Huang X.H., Wang K., Li J.C., Xie X.F., Shen C.L., Li L.J., Zheng Q.S. Bioequivalence evaluation of two formulations of pidotimod using a limited sampling strategy. Biomed. Pharmacother. 2013; 67 (6): 475–480.

18. Carta S., Silvestri M., Rossi G.A. Modulation of airway epithelial cell functions by Pidotimod: NF-kB cytoplasmatic expression and its nuclear translocation are associated with an increased TLR-2 expression. Italian J. Pediatr. 2013; 39: 29.

19. Anisimova N.Yu., Dolzhikova Yu.M., Kokushkov D.V, Borisova, T.V., Chikileva I.O., Sokurenko S.I., Kiselevskii M.V., Karaulov A.V. Features cytokine profile in patients with bronchial asthma in the acute stage. Sechenovskii vestnik = Sechenov bulletin. 2011; 1 (3) –2(4): 26–30.

20. Yarilin A.A. Immunologiya [Immunology]. Moscow, GOETAR-Media, 2010. 752 p.

21. Chun Y.H., Park J.Y., Lee H., Kim H.S., Won S., Joe H.J., Chung W.J., Yoon J.-S., Kim H.H., Kim J.T., Lee J.S. Rhinovirus-infected epithelial cells produce more IL-8 and RANTES compared with other respiratory viruses allergy. Asthma Immunol. Res. 2013; 5 (4): 216–223.

22. Edwards M.R., Bartlett N.W., Hussell T., Openshaw P., Johnston S.L. The microbiology of asthma. Nat. Rev. Microbiol. 2012; 10: 459–471.

23. Ling-Xin S. et al. Influence of pidotimod on the IL-16, immunoglobulin and T cell subsets in asthmatic children. J. Clin. Pediatr. 2011; 29 (8).

24. Shuqin Z., Yuan Y. Efficacy of pidotimod in treatment of bronchial asthma in children. Shandong Yiyao. 2010; 50 (8): 74–75.

25. Carta S., Silvestri M., Rossi G.A. Modulation of airway epithelial cell functions by Pidotimod: NF-kB cytoplasmatic expression and its nuclear translocation are associated with an increased TLR-2 expression. Italian J. Pediatr. 2013; 39: 29.

26. Zuccotti G.V. et al. Immunomodulating activity of Pidotimod in children with Down syndrome. J. Biol. Regul. Homeost. Agents. 2013; 27 (1): 253–258.

27. Grachev A.N. Geterogennost' i funktsional'naya plastichnost' makrofagov vtorogo tipa aktivatsii. Avtoref. … dis. dokt. biol. nauk [Heterogeneity and Functional Plasticity of Macrophage Activation of the Second Type. Author’s abstract]. Moscow, 1998. 40 p.

28. Wang J., Li F., Sun R., Gao X., Wei H., Li L.-J., Tian Z. Bacterial colonization dampens influenza-mediated acute lung injury via induction of M2 alveolar macrophages. Nat. Commun. 2013; 3. Doi: 10.1038/3106

29. Capsoni F., Minonzio F., Ongari A.M., Girardello R., Zanussi C. Evaluation of the kinetics of the immunomodulating activity of Pidotimod on human neutrophils. Pharmacol. Res. 1992; 26 (Suppl. 2): 172–173.

30. Taramelli D., Malabarba M.G., Basilico N., Sala G., Mattina R., Cocuzza C. Effects of pidotimod on macrophage functions in methylprednisolone-treated mice. Arzneimittelforschung. 1994; 44 (12A): 1425–1430.

31. Du X.F., Jiang C.Z., Wu C.F., Won E.K., Choung S.Y. Synergistic immunostimulating activity of pidotimod and red ginseng acidic polysaccharide against cyclophosphamide-induced immunosuppression. Arch. Pharm. Res. 2008; 31, (9): 1153–1159.

32. Migliorati G., Nicoletti I., Riccardi C. Immunomodulating activity of pidotimod. Arzneimittelforschung. 1994; 44 (12A): 1421–1424.

33. Hu X. et al. The detailed analysis of the changes of murine DC induced by thymic peptide pidotimod. Hum. Vacc. & Immunother. 2012; 8 (9): 1250–1258.

34. Gourgiotis D., Papandopoulos N.G., Bossios A. Immune modulator pidotimod decreases the in vitro expression of CD30 in peripheral blood mononuclear cells of atopic asthmatic and normal children. J. Asthma. 2004; 41 (3): 285–287.

35. Zemskov A.M., Zemskov V.M., Karaulov A.V., Novikova L.A. Klinicheskaya immunologiya i allergologiya [Clinical Immunology and Allergology]. Voronezh, 1997. 160 p.

36. Karaulov A.V. Immunomodulators: from past to future. Effektivnaya farmakoterapiya = Effective pharmacotherapy. 2013; 27 (2): 4–5.


Для цитирования:


Караулов А.В. КАКИЕ ИММУНОМОДУЛЯТОРЫ НЕОБХОДИМЫ ЧАСТО БОЛЕЮЩИМ ДЕТЯМ? ОТ ПОНИМАНИЯ МЕХАНИЗМОВ ДЕЙСТВИЯ ПРЕПАРАТА К КЛИНИЧЕСКОЙ ЭФФЕКТИВНОСТИ. Вопросы современной педиатрии. 2014;13(1):119-123. https://doi.org/10.15690/vsp.v13i1.921

For citation:


Karaulov A.V. WHICH IMMUNOMODULATORS ARE INDICATED TO FREQUENTLY ILL CHILDREN? FROM UNDERSTANDING OF MECHANISMS OF ACTION TO CLINICAL EFFICACY. Current Pediatrics. 2014;13(1):119-123. (In Russ.) https://doi.org/10.15690/vsp.v13i1.921

Просмотров: 394


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)